BYBoyuan Yao

Boyuan Yao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Boyuan Yao has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diagnostic Accuracy and Value of CXCR4-targeted PET/MRI Using 68Ga-Pentixafor for Tumor Localization in Cushing Disease

    by Yue Wu, Yanfei Wu, Boyuan Yao, Shuhua Ren, Shiman Wu, Wenting Rui, Min He, Shuo Zhang, Yifei Yu, Hongying Ye, et al.

    In a prospective study involving 43 participants with Cushing disease, the incorporation of gallium 68 (68Ga) pentixafor PET/MRI demonstrated promising sensitivity, which was higher than contrast-enhanced MRI alone in localizing adrenocorticotropic hormone–secreting pituitary tumors.


  • Characterization of Somatotrope Cell Expansion in Response to GHRH in the Neonatal Mouse Pituitary

    by Richard L Gonigam, Karen E Weis, Xiyu Ge, Boyuan Yao, Qilin Zhang, Lori T Raetzman

    In humans and mice, loss-of-function mutations in growth hormone–releasing hormone receptor (GHRHR) cause isolated GH deficiency. The mutant GHRHR mouse model, GhrhrLit/Lit (LIT), exhibits loss of serum GH, but also fewer somatotropes. However, how loss of GHRH signaling affects expansion of stem and progenitor cells giving rise to GH-producing cells is unknown. LIT mice and wild-type littermates were examined for differences in proliferation and gene expression of pituitary lineage markers by quantitative reverse transcription polymerase chain reaction and immunohistochemistry at postnatal day 5 (p5) and 5 weeks. At p5, the LIT mouse shows a global decrease in pituitary proliferation measured by proliferation marker Ki67 and phospho-histone H3. This proliferative defect is seen in a pituitary cell expressing POU1F1 with or without GH. SOX9-positive progenitors show no changes in proliferation in p5 LIT mice. Additionally, the other POU1F1 lineage cells are not decreased in number; rather, we observe an increase in lactotrope cell population as well as messenger RNA for Tshb and Prl. In the 5-week LIT pituitary, the proliferative deficit in POU1F1-expressing cells observed neonatally persists, while the number and proliferative proportion of SOX9 cells do not appear changed. Treatment of cultured pituitary explants with GHRH promotes proliferation of POU1F1-expressing cells, but not GH-positive cells, in a mitogen-activated protein kinase–dependent manner. These findings indicate that hypothalamic GHRH targets proliferation of a POU1F1-positive cell, targeted to the somatotrope lineage, to fine tune their numbers.


  • Top Cited Papers
    Open Access

    Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma

    by Qilin Zhang, Lijiang Fei, Rui Han, Ruofan Huang, Yongfei Wang, Hong Chen, Boyuan Yao, Nidan Qiao, Zhe Wang, Zengyi Ma, et al.

    Skull base chordoma (SBC) is a bone cancer with a high recurrence rate, high radioresistance rate, and poorly understood mechanism. Here, we profiled the transcriptomes of 90,691 single cells, revealed the SBC cellular hierarchies, and explored novel treatment targets. We identified a cluster of stem-like SBC cells that tended to be distributed in the inferior part of the tumor. Combining radiated UM-Chor1 RNA-seq data and in vitro validation, we further found that this stem-like cell cluster is marked by cathepsin L (CTSL), a gene involved in the packaging of telomere ends, and may be responsible for radioresistance. Moreover, signatures related to partial epithelial–mesenchymal transition (p-EMT) were found to be significant in malignant cells and were related to the invasion and poor prognosis of SBC. Furthermore, YL-13027, a p-EMT inhibitor that acts through the TGF-β signaling pathway, demonstrated remarkable potency in inhibiting the invasiveness of SBC in preclinical models and was subsequently applied in a phase I clinical trial that enrolled three SBC patients. Encouragingly, YL-13027 attenuated the growth of SBC and achieved stable disease with no serious adverse events, underscoring the clinical potential for the precision treatment of SBC with this therapy. In summary, we conducted the first single-cell RNA sequencing of SBC and identified several targets that could be translated to the treatment of SBC.